ANDOVER, Mass., July 30, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2025.Recent Highlights Total revenue of $157.4 million in the second quarter of 2025, a 38% increase compared to the second quarter of 2024 Generated net income of $34.9 million or $0.92 per fully diluted share ...